Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutations.

Haematologica·2026
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

American journal of hematology·2026
Same author

A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement.

Blood advances·2026
Same author

Prospective Pilot Study of <sup>11</sup>C-acetate and <sup>18</sup>F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple Myeloma.

Molecular imaging and biology·2026

Related Experiment Video

Updated: Sep 10, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.6K

Curing the Incurable: TP53 Mutated Myeloid Neoplasms.

Nathan Punwani1, Saurabh Chhabra1

  • 1Mayo Clinic Arizona, Phoenix, AZ.

Clinical Lymphoma, Myeloma & Leukemia
|August 23, 2025
PubMed
Summary

TP53 mutations in myeloid cancers like AML and MDS indicate a poor prognosis. These alterations create an immunosuppressive bone marrow environment, worsening outcomes and impacting treatment strategies.

Keywords:
AMLAllogeneic stem cell transplantBone marrowFlotetuzumabIadademstatMDS

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Related Experiment Videos

Last Updated: Sep 10, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

261
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • TP53 gene mutations are critical in myeloid neoplasms, affecting 13% of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • TP53 alterations are linked to a poor prognosis, especially with protein hyper-expression or multi-hit genetic events.
  • These mutations contribute to an immunosuppressive bone marrow microenvironment, worsening patient outcomes.

Purpose of the Study:

  • To survey the pathobiology of TP53 mutated/hyper-expressed myeloid disease.
  • To examine its classification schema and immunologic ramifications.
  • To explore differential prognoses based on chromosomal and variant allele frequency (VAF) settings and outline therapeutic options.

Main Methods:

  • Review of existing literature on TP53 mutations in myeloid neoplasms.
  • Analysis of pathobiology, classification, and immunologic impact.
  • Exploration of prognostic factors including chromosomal alterations and VAF.
  • Survey of current and emerging therapeutic strategies, including allogeneic stem cell transplant.

Main Results:

  • TP53 mutations and hyper-expression are associated with dismal prognosis in AML and MDS.
  • Specific genetic contexts (biallelic loss, 17p deletion, high VAF) worsen outcomes.
  • The bone marrow microenvironment is rendered immunosuppressive by TP53 alterations.

Conclusions:

  • TP53 mutations significantly impact myeloid neoplasm prognosis by altering the bone marrow immune microenvironment.
  • Understanding these genetic and immunologic factors is crucial for developing effective therapeutic strategies.
  • Further research into novel treatments and the role of stem cell transplant is warranted.